Thursday, September 26, 2019 7:50:24 AM
Ref: Glutamate/GABA levels - for several years we have seen graphics and diagrams of the many illnesses that could be corrected by 2-73. I'm thinking that the preliminary Rett results regarding the correction of Glutamate /GABA levels really does tie in with the possible application across multiple indications and the benefit(ratio correction) appears to be measurable.
"Additionally, after seven weeks of treatment, blood levels of the neurotransmitter glutamate decreased significantly, while levels of another neurotransmitter, GABA, or gamma-aminobutyric acid, increased significantly. A neurotransmitter is a chemical molecule that allows nerve cells to communicate. In Rett syndrome, there tend to be abnormally high glutamate levels and abnormally low GABA levels. As such, these results suggest a “balancing” of neurotransmitter levels."
https://rettsyndromenews.com/2019/09/19/preliminary-trial-data-anavex-2-73-rett-syndrome-suggest-safety-efficacy/
Too much Glutamate?
"An excess of glutamate is a primary contributing factor to a wide variety of neurological disorders like autism, ALS, Parkinson’s schizophrenia, migraines, restless leg syndrome, Tourette’s, pandas, fibromyalgia, multiple sclerosis, Huntington’s chorea, and seizures. As well as atrial fibrillation, insomnia, bedwetting, hyperactivity, OCD, bipolar disorder, anxiety disorders, and STIMS (repetitive self-stimulatory behaviors like rocking, pacing, body spinning, hand-flapping, lining up or spinning toys, echolalia, repeating rote phrases or other repetitive body movements or movement of objects that are commonly seen in autistic children), stiff person syndrome, and an increased risk of stroke.
Too much glutamate can also increase eosinophils (a particular type of white blood cell) which result in inflammation, impair blood vessels that lead to migraines and blood pressure irregularities, and impair other areas of the brain like the hypothalamus, hippocampal neurons, and Purkinje neurons which affect speech and language".
Not enough GABA?
"Insufficient levels of GABA result in nervousness, anxiety and panic disorders, aggressive behavior, decreased eye contact and anti-social behavior, attention deficit, problems with eye-focusing (like that seen in autistic children when both eyes are focused inward towards the nose or waver back and forth in a horizontal or vertical movement), chronic pain syndrome,s and much more. It may also contribute to GERD as it is needed to help regulate the lower part of the esophagus."
and
"Gamma-aminobutyric acid is found in almost every area of the brain, but the hypothalamus contains a very high level of GABA receptors, so it is vital for its many functions like regulating sleep, body temperature, appetite, thirst, sexual arousal and desire, and action of the pituitary, HPA axis, and the autonomic nervous system. The primary role of the hypothalamus is to maintain homeostasis throughout the body, and without enough GABA production, this will not happen."
https://www.holistichelp.net/blog/how-to-increase-gaba-and-balance-glutamate/
If 2-73 is able to correct the Glutamate/GABA imbalance it really looks like that could be beneficial and applicable in many ways.
IMO
"Additionally, after seven weeks of treatment, blood levels of the neurotransmitter glutamate decreased significantly, while levels of another neurotransmitter, GABA, or gamma-aminobutyric acid, increased significantly. A neurotransmitter is a chemical molecule that allows nerve cells to communicate. In Rett syndrome, there tend to be abnormally high glutamate levels and abnormally low GABA levels. As such, these results suggest a “balancing” of neurotransmitter levels."
https://rettsyndromenews.com/2019/09/19/preliminary-trial-data-anavex-2-73-rett-syndrome-suggest-safety-efficacy/
Too much Glutamate?
"An excess of glutamate is a primary contributing factor to a wide variety of neurological disorders like autism, ALS, Parkinson’s schizophrenia, migraines, restless leg syndrome, Tourette’s, pandas, fibromyalgia, multiple sclerosis, Huntington’s chorea, and seizures. As well as atrial fibrillation, insomnia, bedwetting, hyperactivity, OCD, bipolar disorder, anxiety disorders, and STIMS (repetitive self-stimulatory behaviors like rocking, pacing, body spinning, hand-flapping, lining up or spinning toys, echolalia, repeating rote phrases or other repetitive body movements or movement of objects that are commonly seen in autistic children), stiff person syndrome, and an increased risk of stroke.
Too much glutamate can also increase eosinophils (a particular type of white blood cell) which result in inflammation, impair blood vessels that lead to migraines and blood pressure irregularities, and impair other areas of the brain like the hypothalamus, hippocampal neurons, and Purkinje neurons which affect speech and language".
Not enough GABA?
"Insufficient levels of GABA result in nervousness, anxiety and panic disorders, aggressive behavior, decreased eye contact and anti-social behavior, attention deficit, problems with eye-focusing (like that seen in autistic children when both eyes are focused inward towards the nose or waver back and forth in a horizontal or vertical movement), chronic pain syndrome,s and much more. It may also contribute to GERD as it is needed to help regulate the lower part of the esophagus."
and
"Gamma-aminobutyric acid is found in almost every area of the brain, but the hypothalamus contains a very high level of GABA receptors, so it is vital for its many functions like regulating sleep, body temperature, appetite, thirst, sexual arousal and desire, and action of the pituitary, HPA axis, and the autonomic nervous system. The primary role of the hypothalamus is to maintain homeostasis throughout the body, and without enough GABA production, this will not happen."
https://www.holistichelp.net/blog/how-to-increase-gaba-and-balance-glutamate/
If 2-73 is able to correct the Glutamate/GABA imbalance it really looks like that could be beneficial and applicable in many ways.
IMO
They said "You should be on the stage!" (As in - the next stage out of town)
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
